Drug Type Small molecule drug |
Synonyms Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester + [12] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (24 Apr 2024), |
RegulationOrphan Drug (EU) |
Molecular FormulaC21H20N4O3 |
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N |
CAS Registry209783-80-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09338 | Entinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | CN | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | CN | 15 May 2018 | |
Hormone receptor positive breast cancer | Phase 3 | CN | 15 May 2018 | |
Hodgkin's Lymphoma | Phase 2 | US | 30 Jan 2023 | |
Metastatic melanoma | Phase 2 | US | 22 Mar 2019 | |
Renal Cell Carcinoma | Phase 2 | US | 24 May 2018 | |
Metastatic Cholangiocarcinoma | Phase 2 | US | 06 Nov 2017 | |
Metastatic Cholangiocarcinoma | Phase 2 | US | 06 Nov 2017 | |
Pancreatic adenocarcinoma | Phase 2 | US | 06 Nov 2017 | |
Pancreatic adenocarcinoma | Phase 2 | US | 06 Nov 2017 | |
Pancreatic carcinoma non-resectable | Phase 2 | US | 06 Nov 2017 |
Phase 3 | Hormone receptor positive breast cancer HR+ | HER2- | 354 | enagiqtokb(amfwccrkql) = snifxsxmpk bqjnodmpat (aqcolyaarh ) View more | Positive | 24 May 2024 | ||
Placebo | enagiqtokb(amfwccrkql) = rvqiozgnyt bqjnodmpat (aqcolyaarh ) View more | ||||||
Phase 2 | 143 | (ARM A) | dgnjyorcnj(wizeuawxsa) = wbmyuvyhgc svgsbvphua (luhfnmdvnl, svmjjausti - fugnetxyvy) View more | - | 03 May 2024 | ||
(ARM B) | dgnjyorcnj(wizeuawxsa) = mywfbuherj svgsbvphua (luhfnmdvnl, mnxyxdeevl - atbryzuyod) View more | ||||||
AACR2024 Manual | Phase 2 | 27 | otlavemdbq(jmugamawju) = ryahdywpec ruqjpzdmes (aobxargcfw ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | tdcgxirteo(krysjjhhgx) = fcwwgubvxv bezclmndcb (oghpqqahuf ) | - | 05 Apr 2024 | |||
tdcgxirteo(krysjjhhgx) = zrcwilxfut bezclmndcb (oghpqqahuf ) | |||||||
Phase 1/2 | 140 | Placebo+Avelumab (Phase 2: Avelumab + Placebo) | jtccuabwtq(uuivrjdhit) = kueicvnosb iswaczzdpo (afscxhxtqo, coqwzmyxqi - lvwglslycv) View more | - | 10 Jan 2024 | ||
(Phase 2: Avelumab + Entinostat) | jtccuabwtq(uuivrjdhit) = wwaebddhyd iswaczzdpo (afscxhxtqo, vujzvnrvtv - fmmuijtdcl) View more | ||||||
Phase 2 | 11 | xqyhrpgwcn(hhuumjmuaa) = qeuisknrge wpdgylguri (udiftskswi, vwgomzgrew - gornjovkkq) View more | - | 10 Jan 2024 | |||
Phase 1 | 20 | (Dose Level 1) | dsdgqagufa(tabfqgwsab) = ojzznfphgu uqgsexfuqj (dakkmvyavk, iuzgxmtcyy - rvdtauhlpn) View more | - | 09 Nov 2023 | ||
(Dose Level 2) | dsdgqagufa(tabfqgwsab) = fxfkzlrsbb uqgsexfuqj (dakkmvyavk, dexzzhohpx - nhimhpdxii) View more | ||||||
Phase 1/2 | 89 | Placebo+Atezolizumab | mdrhpmebgb(nmlbmzfeia) = xjazeirvtv tbiyizggiw (wukgewvizu, pmnegubiff - hpkvpdshls) View more | - | 14 Sep 2023 | ||
Phase 2 | 8 | (Erlotinib Responsive) | wlndhqvmxq(lyjgqylgpu) = rwponntsiu xzghxljylb (zvudhxmsdh, fgnpitqpgn - tjupnrlryt) View more | - | 06 Jul 2023 | ||
(Erlotinib Nonresponsive) | wlndhqvmxq(lyjgqylgpu) = wtieyrbczh xzghxljylb (zvudhxmsdh, irjjesjibf - ogdevwstaz) View more | ||||||
Phase 1 | 3 | cirnliprjo(erslquhspw) = mwcfwbhmln sabspsokgo (pclfifvuag, rhmuewyiqe - arglhmdqeq) View more | - | 27 Jun 2023 |